Skip to content
OpenCapital
Get started

Mineralys Therapeutics, Inc. MLYS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
——
ITG
Integer HoldingsITGR
——

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K—
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.26B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Mineralys Therapeutics, Inc. (MLYS) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $46.98M in Q4 2025.
What is the long-term trend for Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value has grown at a 288.5% compound annual growth rate (CAGR), from $3.11M to $46.98M.